Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2022
August 08, 2022 at 05:12 am EDT
Share
Changzhou Qianhong Biopharma CO.,LTD reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 1,135.41 million compared to CNY 872.5 million a year ago. Revenue was CNY 1,136.89 million compared to CNY 873.01 million a year ago. Net income was CNY 201.86 million compared to CNY 89.15 million a year ago. Basic earnings per share from continuing operations was CNY 0.1615 compared to CNY 0.0715 a year ago. Diluted earnings per share from continuing operations was CNY 0.1615 compared to CNY 0.0715 a year ago.
Changzhou Qianhong Biopharma CO., LTD is a China-based company, principally engaged in the research and development, production and distribution of freeze-drying powder, freeze-drying powder injections, small volume injections, tablets, hard capsules, granules and bulk drugs, among others. The Company mainly provides liquaemin sodium raw materials and preparations, applied to prevent and treat thromboembolism desease; kallidinogen preparations, applied in the treatment of micro-circulation disorder disease, asparaginase bulk drugs and preparations, applied in the treatment of acute lymphoblastic leukemia, as well as compound digestive enzyme capsules II. The Company distributes its products within domestic market and to overseas markets.
CHANGZHOU QIANHONG BIOPHARMA CO.,LTD 
